ReWalk Robotics (LFWD) 10-Q 7 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 06, 2022
Cover [Abstract]
Entity Central Index Key	0001607962
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Entity File Number	001-36612
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Incorporation State or Country Code	L3
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	3 Hatnufa Street
Entity Address, Address Line Two	Floor 6
Entity Address, City or Town	Yokneam Ilit
Entity Address, Country	IL
Entity Address, Postal Zip Code	2069203
Title of 12(b) Security	Ordinary shares, par value NIS 0.25
Trading Symbol	RWLK
Name of Exchange on which Security is Registered	NASDAQ
City Area Code	972
Local Phone Number	4.959.0123
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		62,018,860

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 74,027	$ 88,337
Trade receivable, net	447	585
Prepaid expenses and other current assets	1,091	610
Inventories	3,330	2,989
Total current assets	78,895	92,521
LONG-TERM ASSETS
Restricted cash and other long-term assets	1,001	1,064
Operating lease right-of-use assets	638	881
Property and equipment, net	237	284
Total long-term assets	1,876	2,229
Total assets	80,771	94,750
CURRENT LIABILITIES
Current maturities of operating leases	606	641
Trade payables	1,908	1,384
Employees and payroll accruals	989	1,142
Deferred revenues	369	316
Other current liabilities	348	555
Total current liabilities	4,220	4,038
LONG-TERM LIABILITIES
Deferred revenues	808	866
Non-current operating leases	85	418
Other long-term liabilities	68	45
Total long-term liabilities	961	1,329
Total liabilities	5,181	5,367
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS’ EQUITY
Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at September 30, 2022 and December 31, 2021; Issued: 62,901,945 and 62,480,163 shares as of September 30, 2022 and December 31, 2021 respectively; Outstanding: 62,717,316 and 62,480,163 shares as of September 30, 2022 and December 31, 2021 respectively	4,678	4,661
Additional paid-in capital	279,519	278,903
Treasury Shares at cost, 184,629 ordinary shares	(170)	0
Accumulated deficit	(208,437)	(194,181)
Total shareholders' equity	75,590	89,383
Total liabilities and shareholders' equity	$ 80,771	$ 94,750

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Ordinary shares, par value per share	₪ 0.25	₪ 0.25
Ordinary shares, authorized	120,000,000	120,000,000
Ordinary shares, issued	62,901,945	62,480,163
Ordinary shares, outstanding	62,717,316	62,480,163
Treasury stock common shares	184,629

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 886	$ 1,972	$ 3,332	$ 4,724
Cost of revenues	665	832	2,100	2,150
Gross profit	221	1,140	1,232	2,574
Operating expenses:
Research and development, net	1,065	638	2,928	2,243
Sales and marketing	2,588	1,821	7,119	5,105
General and administrative	2,001	1,343	5,282	4,050
Total operating expenses	5,654	3,802	15,329	11,398
Operating loss	(5,433)	(2,662)	(14,097)	(8,824)
Financial expenses, net	1	27	69	14
Loss before income taxes	(5,434)	(2,689)	(14,166)	(8,838)
Taxes on income (tax benefit)	26	(14)	90	40
Net loss	$ (5,460)	$ (2,675)	$ (14,256)	$ (8,878)
Net loss per ordinary share, basic	$ (0.09)	$ (0.06)	$ (0.23)	$ (0.21)
Net loss per ordinary share, diluted	$ (0.09)	$ (0.06)	$ (0.23)	$ (0.21)
Weighted average number of shares used in computing net loss per ordinary share, basic	62,793,847	46,570,130	62,611,580	43,021,972
Weighted average number of shares used in computing net loss per ordinary share, diluted	62,793,847	46,570,130	62,611,580	43,021,972

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands		Ordinary Shares	Additional Paid-in Capital	Treasury stock	Accumulated deficit	Total
Balance at Dec. 31, 2020		$ 1,827	$ 201,392	$ 0	$ (181,445)	$ 21,774
Balance, shares at Dec. 31, 2020		25,332,225
Share-based compensation to employees and non-employees			599	0	0	599
Issuance of ordinary shares upon vesting of employees and non-employees RSUs		$ 29	(29)	0	0	0
Issuance of ordinary shares upon vesting of employees and non-employees RSUs, Shares		366,796
Issuance of ordinary shares in a “registered direct" offering, net of issuance expenses in the amount of $3,228	[1]	$ 1,199	26,918	0	0	28,117
Issuance of ordinary shares in a “registered direct" offering, net of issuance expenses in the amount of $3,228 Shares	[1]	15,403,014
Exercise of pre-funded warrants and warrants	[1],[2]	$ 771	14,289	0	0	15,060
Exercise of pre-funded warrants and warrants, Shares	[1],[2]	10,425,258
Issuance of ordinary shares in a “best effort” offering, net of issuance expenses in the amount of $3,679	[1]	$ 832	35,489	0	0	36,321
Issuance of ordinary shares in a “best effort” offering, net of issuance expenses in the amount of $3,679, Shares	[1]	10,921,502
Net loss			0	0	(8,878)	(8,878)
Balance at Sep. 30, 2021		$ 4,658	278,658	0	(190,323)	92,993
Balance, shares at Sep. 30, 2021		62,448,795
Balance at Jun. 30, 2021		$ 3,394	250,332	0	(187,648)	66,078
Balance, shares at Jun. 30, 2021		46,201,052
Share-based compensation to employees and non-employees			231	0	0	231
Issuance of ordinary shares upon vesting of employees and non-employees RSUs		$ 18	(18)	0	0	0
Issuance of ordinary shares upon vesting of employees and non-employees RSUs, Shares		234,225
Issuance of ordinary shares in a “registered direct" offering, net of issuance expenses in the amount of $3,228	[1]	$ 1,199	26,918	0	0	28,117
Issuance of ordinary shares in a “registered direct" offering, net of issuance expenses in the amount of $3,228 Shares	[1]	15,403,014
Exercise of pre-funded warrants and warrants	[1],[2]	$ 47	1,195	0	0	1,242
Exercise of pre-funded warrants and warrants, Shares	[1],[2]	610,504
Net loss			0	0	(2,675)	(2,675)
Balance at Sep. 30, 2021		$ 4,658	278,658	0	(190,323)	92,993
Balance, shares at Sep. 30, 2021		62,448,795
Balance at Dec. 31, 2021		$ 4,661	278,903	0	(194,181)	89,383
Balance, shares at Dec. 31, 2021		62,480,163
Share-based compensation to employees and non-employees			646	0	0	646
Issuance of ordinary shares upon vesting of employees and non-employees RSUs		$ 30	(30)	0	0	0
Issuance of ordinary shares upon vesting of employees and non-employees RSUs, Shares		421,782
Treasury shares		$ (13)	0	(170)	0	(183)
Treasury Shares, Shares		(184,629)
Net loss			0	0	(14,256)	(14,256)
Balance at Sep. 30, 2022		$ 4,678	279,519	(170)	(208,437)	75,590
Balance, shares at Sep. 30, 2022		62,717,316
Balance at Jun. 30, 2022		$ 4,675	279,215	0	(202,977)	80,913
Balance, shares at Jun. 30, 2022		62,678,308
Share-based compensation to employees and non-employees			320	0	0	320
Issuance of ordinary shares upon vesting of employees and non-employees RSUs		$ 16	(16)	0	0	0
Issuance of ordinary shares upon vesting of employees and non-employees RSUs, Shares		223,637
Treasury shares		$ (13)	0	(170)	0	(183)
Treasury Shares, Shares		(184,629)
Net loss			0	0	(5,460)	(5,460)
Balance at Sep. 30, 2022		$ 4,678	$ 279,519	$ (170)	$ (208,437)	$ 75,590
Balance, shares at Sep. 30, 2022		62,717,316
[1]See Note 7e to the condensed consolidated financial statements[2]See Note 7c to the condensed consolidated financial statements

CONDENSED STATEMENTS OF CHANG_2

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Registered Direct [Member]
Issuance expenses, amount	$ 3,228	$ 3,228
Best Efforts [Member]
Issuance expenses, amount		$ 3,679

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Cash flows used in operating activities:
Net loss		$ (14,256)	$ (8,878)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		161	210
Share-based compensation to employees and non-employees		646	599
Deferred taxes		2	(57)
Finance expense, net		182	0
Trade receivables, net		138	(591)
Prepaid expenses, operating lease right-of-use assets and other assets		(115)	320
Inventories		(550)	372
Trade payables		524	(624)
Employees and payroll accruals		(153)	20
Deferred revenues		(5)	8
Operating lease liabilities and other liabilities		(552)	(282)
Net cash used in operating activities		(13,978)	(8,903)
Cash flows used in investing activities:
Purchase of property and equipment		(25)	(28)
Net cash used in investing activities		(25)	(28)
Cash flows from financing activities:
Purchase of treasury shares		(183)	0
Issuance of ordinary shares in a private placement, net of issuance expenses paid in the amount of $ 3,679 (1)	[1]	0	36,321
Issuance of ordinary shares in a "registered direct" offerings, net of issuance expenses in the amount of $2,918 (1)	[1]	0	28,427
Exercise of pre-funded warrants and warrants (1) (2)	[1],[2]	0	15,060
Net cash provided by (used in) financing activities		(183)	79,808
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash		(182)	0
Increase (decrease) in cash, cash equivalents, and restricted cash		(14,186)	70,877
Cash, cash equivalents, and restricted cash at beginning of period		89,050	21,054
Cash, cash equivalents, and restricted cash at end of period		74,682	91,931
Supplemental disclosures of non-cash flow information
“Registered direct” offerings issuance cost not yet paid (1)	[1]	0	310
Classification of other current assets to property and equipment, net		22	16
Classification of inventory to property and equipment, net		67	32
Classification of inventory to other current assets		207	72
Supplemental cash flow information:
Cash and cash equivalents		74,027	91,227
Restricted cash included in other long-term assets		655	704
Total Cash, cash equivalents, and restricted cash		$ 74,682	$ 91,931
[1]See Note 7e to the condensed consolidated financial statements.[2]See Note 7c to the condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Registered Direct [Member]
Issuance expenses paid	$ 2,918
Private Placement [Member]
Issuance expenses paid	$ 3,679

GENERAL

GENERAL	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1: GENERAL a. ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. b. RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) incorporated under the laws of Germany on January 14, 2013.   The Company is designing, developing, and commercializing robotic exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company has developed and is continuing to commercialize the ReWalk, an exoskeleton designed for individuals with paraplegia that uses its patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. The ReWalk system consists of a light wearable brace support suit which integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. Additionally, the Company developed and, in June 2019, started to commercialize the ReStore following receipt of European Union CE mark and United States Food and Drug Administration (“FDA”) clearance. The ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke. The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in Germany and the United States, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States. RRG markets and sells the Company’s products mainly in Germany and Europe.   During the second quarter of 2020, the Company finalized two separate agreements to distribute additional product lines in the U.S. market. The Company is the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States and has distribution rights for the MYOLYN MyoCycle FES cycles to U.S. rehabilitation clinics and personal sales through the U.S. Department of Veterans Affairs (“VA”) hospitals. These new products have improved the Company’s product offering to clinics as well as patients within the VA as they both have similar clinician and patient profiles. c. The worldwide spread of COVID-19 has resulted in a global economic slowdown and is expected to continue to disrupt general business operations until the disease is contained. This has had a negative impact on the Company’s sales and results of operations since the start of the pandemic, and the Company expects that it will continue to negatively affect its sales and results of operations; however, the Company is currently unable to predict the scale and duration of that impact. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update of its accounting estimates or judgments or revision of the carrying value of its assets or liabilities. This determination may change as new events occur and additional information is obtained. Actual results could differ from management’s estimates and judgments, and any such differences may be material to the Company’s financial statements. d. As

UNAUDITED INTERIM CONDENSED CON

UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2022
Unaudited Interim Condensed Consolidated Financial Statements [Abstract]
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 2: UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The These financial statements and accompanying notes should be read in conjunction with the 2021 consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2021 filed with the SEC on February 24, 2022, as amended on May 2, 2022 (the “2021 Form 10-K”). There have been no changes in the significant accounting policies from those that were disclosed in the audited consolidated financial statements for the fiscal year ended December 31, 2021 included in the 2021 Form 10-K, unless otherwise stated.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3: SIGNIFICANT ACCOUNTING POLICIES a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Units placed $ 751 $ 1,855 $ 2,986 $ 4,310 Spare parts, warranties and other 135 117 346 414 Total Revenues $ 886 $ 1,972 $ 3,332 $ 4,724 Units placed The Company currently offers five products: (1) ReWalk Personal; (2) ReWalk Rehabilitation; (3) ReStore; (4) MyoCycle; and (5) MediTouch. ReWalk Personal and ReWalk Rehabilitation are units for spinal cord injuries (“SCI Products”). SCI Products are currently designed for everyday use by paraplegic individuals at home and in their communities, and are custom fitted for each user, as well as for use by paraplegia patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. The MyoCycle device uses Functional Electrical Stimulation (“FES”) technology to facilitate therapeutic exercise for persons with muscle weakness or paralysis caused by disorders like spinal cord injury, multiple sclerosis, and stroke. The MediTouch Tutor movement biofeedback product line includes the Arm, Hand, 3D and Leg Tutor devices. These devices are used by physical and occupational therapists to evaluate functional tasks during rehabilitation of neurologic disorders and can also be used by patients remotely at home. Pursuant to two separate distribution agreements entered into during the second quarter of 2020, the Company now markets both the MediTouch and MyoCyle products (together the “Distributed Products”) in the United States for use at home or in the clinic. Units placed includes revenue from sales or rental of SCI Products, ReStore and the Distributed Products. For units placed, the Company recognizes revenues when it transfers control and title has passed to the customer. Each unit placed is considered an independent, unbundled performance obligation. The Company generally does not grant a right of return for its products besides isolated cases where the Company assesses the likelihood of such event to occur based on the Company’s historical experience and estimates. The Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. Revenue is recognized when the Company satisfies a performance obligation by transferring control over promised goods or services to the customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, the Company updated its service policy for SCI Products to include a five-year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. The ReStore device Is offered with a two-year warranty which is considered as assurance type warranty. The Distributed Products are offered with an assurance-type warranty that is covered by the vendor ranging from one year to ten years depending on the specific product and part. Contract balances (in thousands) September 30, December 31, 2022 2021 Trade receivable, net (1) $ 447 $ 585 Deferred revenues (1) (2) $ 1,177 $ 1,182 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) During the nine months ended September 30, 2022, $280 thousand of the December 31, 2021, deferred revenues balance was recognized as revenues. Deferred revenue is comprised mainly of unearned revenue related to service type warranty but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. The Company’s unfilled performance obligations as of September 30, 2022, and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1.1 million, which is fulfilled over one to five years. b. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. September 30, December 31, 2022 2021 Customer A 27 % 12 % Customer B 27 % * ) Customer C 19 % * ) Customer D 18 % * ) Customer E * ) 20 % Customer F * ) 18 % Customer G * ) 16 % Customer H * ) 10 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of September 30, 2022 and December 31, 2021, trade receivables are presented net of allowance for doubtful accounts in the amount of $26 thousand and $42 thousand, respectively, and net of sales return reserve of $52 thousand and $43 thousand, respectively. c. Warranty provision For SCI Products the Company determined that the first two years of warranty is an assurance-type warranty. For the ReStore device, the Company determined that the two years warranty is an assurance-type warranty. For Distributed Products the Company determined they are offered with an assurance-type warranty ranging from one year to ten years depending on the specific product and part. For assurance-type warranty the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2021 $ 112 Provision 245 Usage (265 ) Balance at September 30, 2022 $ 92 d. Basic and diluted net loss per ordinary share Basic net loss per ordinary share is computed based on the weighted average number of ordinary shares outstanding during each . For the three and nine months ended September 30, 2022, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,420,894, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect. e. Treasury stock The Company has repurchased its ordinary shares from time to time in the open market and holds such repurchased shares as treasury stock. The Company presents the cost to repurchase treasury stock as a reduction of shareholders’ equity. f. New Accounting Pronouncements Recently Implemented Accounting Pronouncements i. Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and a beneficial conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (“EPS”). ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020 and can be adopted on either a fully retrospective or modified retrospective basis. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted ii. Financial Instruments In June 2016, FASB issued ASU 2016-13, Financial Instruments - –Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. Topic 326 will be effective for the Company beginning on January 1, 2023. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. The Company expects that this guidance will not have a significant impact on the Company’s consolidated financial statements.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4: INVENTORIES The components of inventories are as follows (in thousands): September 30, December 31, 2022 2021 Finished products $ 2,807 $ 2,284 Raw materials 523 705 $ 3,330 $ 2,989 During the nine months ended September 30, 2022, and 2021, the Company wrote off inventory in the amount of $32 and $ 65 thousand, respectively. The write off inventory were recorded in cost of revenue.

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 5: COMMITMENTS AND CONTINGENT LIABILITIES a. Purchase commitments: T b. Operating lease commitment: (i) T (ii) RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2022 and 2025. A subset of the Company’s cars leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $18 thousand as of September 30, 2022. The Company's future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company's condensed consolidated balance sheets as of September 30, 2022, are as follows (in thousands): 2022 $ 165 2023 520 2024 57 2025 14 Total lease payments 756 Less: imputed interest (65 ) Present value of future lease payments 691 Less: current maturities of operating leases (606 ) Non-current operating leases $ 85 Weighted-average remaining lease term (in years) 1.51 Weighted-average discount rate 12.5 % L c. Royalties: The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (the “IIA”) and the Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”). During the three and nine months that ended September 30, 2022, the Company received $23 thousand and $207 thousand respectively from the IIA to fund its research and development efforts. Since the Company’s inception through September 30, 2022, the Company received funding from the IIA and BIRD in the total amount of $ million and $ thousand, respectively. Out of the $ million in funding from the IIA, a total amount of $ million were royalty-bearing grants (as of September 30, 2022, the Company paid royalties to the IIA in the total amount of $ thousand), a total amount of $ thousand was received in consideration of convertible preferred A shares, which were converted after the Company’s initial public offering in September 2014 into , while a total amount of $208 thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to % of the sales of the products and other related revenues generated from such projects, up to % of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. Additionally, the Exclusive License Agreement between the Company and Harvard University’s Wyss Institute for Biologically Inspired Engineering “"Harvard”") requires the Company to pay Harvard royalties on net sales. See note 6 below for more information about the Collaboration Agreement and the License Agreement. Royalties expenses in cost of revenue were $3 and $2 thousand for the three months ended September 30, 2022 and 2021, respectively. For the nine months ended September 30, 2022, and 2021, the royalties expenses were $7 thousand and $8 thousand, respectively. As of September 30, 2022, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the research and development activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) if such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient. d. Liens: A e. Legal Claims: Occasionally, the Company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other legal matters arising, for the most part, in the ordinary course of business. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity, or financial condition. While the outcome of any pending or threatened litigation and other legal matters is inherently uncertain, the Company is not currently party to any material litigation.

RESEARCH COLLABORATION AGREEMEN

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	9 Months Ended
	Sep. 30, 2022
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	NOTE 6: RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement (“Collaboration Agreement”) and an Exclusive License Agreement (“License Agreement”) with Harvard. The Research Collaboration Agreement was amended on May 1, 2017, and April 1, 2018 (as amended, the “Collaboration Agreement”), and the Exclusive License Agreement was amended on April 1, 2018 (as amended, the “License Agreement”), to extend the term of the Collaboration Agreement by one year to May 16, 2022 and reallocate the Company’s quarterly installment payments to Harvard through such date, and to make certain technical changes. On April 30, 2020, the Company and Harvard amended the Collaboration Agreement, which included certain adjustments to the quarterly installments and extended the term an additional three quarters until February 2023. On October 14, 2021, the Company and Harvard further amended the Collaboration Agreement, to make certain adjustments to the quarterly installments and technical changes. The Collaboration Agreement concluded on March 31, 2022. Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The License Agreement required the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of September 30, 2022, the Company achieved three of the milestones which represent all development milestones under the License Agreement. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis. The Company has recorded expenses in the amount of $26 thousand and $14 thousand as research and development expenses related to the License Agreement and to the Collaboration Agreement for the three months ended September 30, 2022, and 2021, respectively. For the nine months ended September 30, 2022, and 2021, the expense were $60 thousand and $334 thousand, respectively. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and the License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 7: SHAREHOLDERS’ EQUITY a. Share option plans: As of September 30, 2022, and December 31, 2021, the Company had reserved 2,934,679 and 233,957 ordinary shares, respectively, for issuance to the Company’s and its affiliates’ respective employees, directors, officers and consultants pursuant to equity awards granted under the Company’s 2014 Incentive Compensation Plan (the “2014 Plan”). Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. There were no options granted during the nine months ended September 30, 2022 , and 2021 . A summary of employees and non-employees share options activity during the nine months ended September 30, 2022, is as follows: Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) O 61,832 $ 38.34 4.55 $ - Granted - - - - Exercised - - - - Forfeited (17,838 ) 31.13 - - O 43,994 $ 41.27 4.64 $ - O 42,440 $ 42.58 4.57 $ - The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. No options were exercised during the three and nine months that ended September 30, 2022, and 2021. The RSUs generally vest over four years, with certain RSUs to non-employee directors vesting quarterly over one year. Any RSUs that is canceled before the vesting becomes available for future grants under the 2014 Plan. A summary of employees and non-employees RSUs activity during the nine months ended September 30, 2022, is as follows: Number of shares underlying outstanding RSUs Weighted average grant date fair value U 1,356,284 $ 1.61 Granted 2,152,757 1.00 Vested (421,782 ) 1.65 Forfeited (210,641 ) 1.53 U 2,876,618 $ 1.15 The weighted average grant date fair value of RSUs granted during the nine months ended September 30, 2022, and 2021, was $1.00 and $1.69 , respectively. As of September 30, 2022, there were $3.0 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the 2014 Plan. This cost is expected to be recognized over a period of approximately 2.9 years. The number of options and RSUs outstanding as of September 30, 2022, is set forth below, with options separated by range of exercise price. Range of exercise price Options outstanding September 30, Weighted average remaining contractual life (years) (1) Options and September 30, Weighted average remaining contractual life (years) (1) RSUs only 2,876,618 - - - $5.37 12,425 6.49 10,871 6.49 $20.42 - $33.75 13,317 5.46 13,317 5.46 $37.14 - $38.75 8,946 1.23 8,946 1.23 $50 - $52.5 6,731 4.72 6,731 4.72 $182.5 - $524.25 2,575 3.10 2,575 3.10 2,920,612 4.64 42,440 4.57 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. b. Share-based awards to non-employee consultants: The Company granted 47,522 fully vested RSUs on June 30, 2022, to a non-employee consultant. As of September 30, 2022, there are no outstanding options or RSUs held by non-employee consultants. c. Warrants to purchase ordinary shares: The following table summarizes information about warrants outstanding and exercisable as of September 30, 2022: Issuance date Warrants outstanding Exercise price per warrant Warrants outstanding exercisable Contractual term (number) (number) December 31, 2015 (1) 4,771 $ 7.500 4,771 See footnote (1) December 28, 2016 (2) 1,908 $ 7.500 1,908 See footnote (1) November 20, 2018 (3) 126,839 $ 7.500 126,839 November 20, 2023 November 20, 2018 (4) 106,680 $ 9.375 106,680 November 15, 2023 February 25, 2019 (5) 45,600 $ 7.187 45,600 February 21, 2024 April 5, 2019 (6) 408,457 $ 5.140 408,457 October 7, 2024 April 5, 2019 (7) 49,015 $ 6.503 49,015 April 3, 2024 June 5, 2019, and June 6, 2019 (8) 1,464,665 $ 7.500 1,464,665 June 5, 2024 June 5, 2019 (9) 87,880 $ 9.375 87,880 June 5, 2024 June 12, 2019 (10) 416,667 $ 6.000 416,667 December 12, 2024 June 10, 2019 (11) 50,000 $ 7.500 50,000 June 10, 2024 February 10, 2020 (12) 28,400 $ 1.250 28,400 February 10, 2025 February 10, 2020 (13) 105,840 $ 1.563 105,840 February 10, 2025 July 6, 2020 (14) 448,698 $ 1.760 448,698 January 2, 2026 July 6, 2020 (15) 296,297 $ 2.278 296,297 January 2, 2026 December 8, 2020 (16) 586,760 $ 1.340 586,760 June 8, 2026 December 8, 2020 (17) 108,806 $ 1.792 108,806 June 8, 2026 February 26, 2021 (18) 5,460,751 $ 3.600 5,460,751 August 26, 2026 February 26, 2021 (19) 655,290 $ 4.578 655,290 August 26, 2026 September 29, 2021 (20) 8,006,759 $ 2.000 8,006,759 March 29, 2027 September 29, 2021 (21) 960,811 $ 2.544 960,811 September 27, 2026 19,420,894 19,420,894 (1) Represents warrants for ordinary shares issuable upon an exercise price of $7.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2022. (2) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (3) Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018. (4) Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018. (5) Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019. (6) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019. (7) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering. (8) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively. (9) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants. (10) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. (11) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants (12) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. During the year ended December 31, 2021, 3,740,100 warrants were exercised for total consideration of $4,675,125. (13) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. During the year ended December 31, 2021, 230,160 warrants were exercised for total consideration of $359,625. (14) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. During the year ended December 31, 2021, 2,020,441 warrants were exercised for total consideration of $3,555,976. (15) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. (16) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. During the year ended December 31, 2021, 3,598,072 warrants were exercised for total consideration of $4,821,416. (17) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. During the year ended December 31, 2021, 225,981 warrants were exercised for total consideration of $405,003. (18) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021. (19) Represents warrants that were issued to the placement agent as compensation for its role in Company’s private placement offering in February 2021. (20) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021. (21) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering. d. Share-based compensation expense for employees and non-employees: The Company recognized non-cash share-based compensation expense for employees and non-employees in the condensed consolidated statements of operations as follows (in thousands): Nine Months Ended September 30, 2022 2021 Cost of revenues $ 10 $ 7 Research and development 60 34 Sales and marketing 167 120 General and administrative 409 438 Total $ 646 $ 599 e. Equity raise: 1. Follow-on offerings and warrants exercise: On February 19, 2021, the Company entered into a purchase agreement with certain institutional and other accredited investors for the issuance and sale of 10,921,502 ordinary shares, par value NIS 0.25 per share at $3.6625 per ordinary share and warrants to purchase up to an aggregate of 5,460,751 ordinary shares with an exercise price of $3.6 per share, exercisable from February 19, 2021 until August 26, 2026. Additionally, the Company issued warrants to purchase up to 655,290 ordinary shares, with an exercise price of $4.578125 per share, exercisable from February 19, 2021 until August 26, 2026, to certain representatives of H.C. Wainwright & Co., LLC (“H.C. Wainwright”) as compensation for its role as the placement agent in our February 2021 Offering. On As of September, 30, 2022 f. Treasury stock: On June 2, 2022, the Company’s Board of Directors approved a share repurchase program to repurchase up to $8 million of its Ordinary Shares, par value NIS 0.25 per share. On July 21, 2022, the Company received approval from an Israeli court for the share repurchase program, valid through January 20, 2023. As of September 30, 2022, pursuant to the Company’s share repurchase program, the Company had repurchased a total of 184,629 of its outstanding ordinary shares at a total cost of $183,540. As to ordinary shares repurchased after September 30, 2022, see Note 10.

FINANCIAL EXPENSES (INCOME), NE

FINANCIAL EXPENSES (INCOME), NET	9 Months Ended
	Sep. 30, 2022
Other Income and Expenses [Abstract]
FINANCIAL EXPENSES (INCOME), NET	NOTE 8: FINANCIAL EXPENSES (INCOME), NET The Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Foreign currency transactions and other $ 1 $ 22 $ 50 $ (6 ) Bank commissions - 5 19 20 $ 1 $ 27 $ 69 $ 14

GEOGRAPHIC INFORMATION AND MAJO

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	NOTE 9: GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: A September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenues based on customer’s location: United States $ 395 $ 821 $ 1,193 $ 1,951 Europe 488 1,148 2,023 2,711 Asia-Pacific 2 1 113 58 Africa 1 2 3 4 Total revenues $ 886 $ 1,972 $ 3,332 $ 4,724 September 30, December 31, 2022 2021 Long-lived assets by geographic region (*): Israel $ 515 $ 629 United States 303 493 Germany 57 43 $ 875 $ 1,165 *) Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets. Nine Months Ended eptember 30, 2022 2021 Major customer data as a percentage of total revenues: Customer A 21.8 % * ) Customer B * ) 12.1 % *) Less than 10%.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10: SUBSEQUENT EVENTS Subsequent to September 30, 2022, the Company repurchased an additional 719,893 of its ordinary shares for an aggregate consideration of $679,844.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Revenue Recognition	a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Units placed $ 751 $ 1,855 $ 2,986 $ 4,310 Spare parts, warranties and other 135 117 346 414 Total Revenues $ 886 $ 1,972 $ 3,332 $ 4,724 Units placed The Company currently offers five products: (1) ReWalk Personal; (2) ReWalk Rehabilitation; (3) ReStore; (4) MyoCycle; and (5) MediTouch. ReWalk Personal and ReWalk Rehabilitation are units for spinal cord injuries (“SCI Products”). SCI Products are currently designed for everyday use by paraplegic individuals at home and in their communities, and are custom fitted for each user, as well as for use by paraplegia patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. The MyoCycle device uses Functional Electrical Stimulation (“FES”) technology to facilitate therapeutic exercise for persons with muscle weakness or paralysis caused by disorders like spinal cord injury, multiple sclerosis, and stroke. The MediTouch Tutor movement biofeedback product line includes the Arm, Hand, 3D and Leg Tutor devices. These devices are used by physical and occupational therapists to evaluate functional tasks during rehabilitation of neurologic disorders and can also be used by patients remotely at home. Pursuant to two separate distribution agreements entered into during the second quarter of 2020, the Company now markets both the MediTouch and MyoCyle products (together the “Distributed Products”) in the United States for use at home or in the clinic. Units placed includes revenue from sales or rental of SCI Products, ReStore and the Distributed Products. For units placed, the Company recognizes revenues when it transfers control and title has passed to the customer. Each unit placed is considered an independent, unbundled performance obligation. The Company generally does not grant a right of return for its products besides isolated cases where the Company assesses the likelihood of such event to occur based on the Company’s historical experience and estimates. The Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. Revenue is recognized when the Company satisfies a performance obligation by transferring control over promised goods or services to the customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, the Company updated its service policy for SCI Products to include a five-year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. The ReStore device Is offered with a two-year warranty which is considered as assurance type warranty. The Distributed Products are offered with an assurance-type warranty that is covered by the vendor ranging from one year to ten years depending on the specific product and part. Contract balances (in thousands) September 30, December 31, 2022 2021 Trade receivable, net (1) $ 447 $ 585 Deferred revenues (1) (2) $ 1,177 $ 1,182 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) During the nine months ended September 30, 2022, $280 thousand of the December 31, 2021, deferred revenues balance was recognized as revenues. Deferred revenue is comprised mainly of unearned revenue related to service type warranty but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. The Company’s unfilled performance obligations as of September 30, 2022, and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1.1 million, which is fulfilled over one to five years.
Concentrations of Credit Risks:	b. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. September 30, December 31, 2022 2021 Customer A 27 % 12 % Customer B 27 % * ) Customer C 19 % * ) Customer D 18 % * ) Customer E * ) 20 % Customer F * ) 18 % Customer G * ) 16 % Customer H * ) 10 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of September 30, 2022 and December 31, 2021, trade receivables are presented net of allowance for doubtful accounts in the amount of $26 thousand and $42 thousand, respectively, and net of sales return reserve of $52 thousand and $43 thousand, respectively.
Warranty provision	c. Warranty provision For SCI Products the Company determined that the first two years of warranty is an assurance-type warranty. For the ReStore device, the Company determined that the two years warranty is an assurance-type warranty. For Distributed Products the Company determined they are offered with an assurance-type warranty ranging from one year to ten years depending on the specific product and part. For assurance-type warranty the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2021 $ 112 Provision 245 Usage (265 ) Balance at September 30, 2022 $ 92
Basic and diluted net loss per ordinary share	d. Basic and diluted net loss per ordinary share Basic net loss per ordinary share is computed based on the weighted average number of ordinary shares outstanding during each . For the three and nine months ended September 30, 2022, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,420,894, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.
Treasury stock	e. Treasury stock The Company has repurchased its ordinary shares from time to time in the open market and holds such repurchased shares as treasury stock. The Company presents the cost to repurchase treasury stock as a reduction of shareholders’ equity.
New Accounting Pronouncements	f. New Accounting Pronouncements Recently Implemented Accounting Pronouncements i. Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and a beneficial conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (“EPS”). ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020 and can be adopted on either a fully retrospective or modified retrospective basis. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted ii. Financial Instruments In June 2016, FASB issued ASU 2016-13, Financial Instruments - –Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. Topic 326 will be effective for the Company beginning on January 1, 2023. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. The Company expects that this guidance will not have a significant impact on the Company’s consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of disaggregation of revenues	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Units placed $ 751 $ 1,855 $ 2,986 $ 4,310 Spare parts, warranties and other 135 117 346 414 Total Revenues $ 886 $ 1,972 $ 3,332 $ 4,724
Schedule of contract balances	September 30, December 31, 2022 2021 Trade receivable, net (1) $ 447 $ 585 Deferred revenues (1) (2) $ 1,177 $ 1,182 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) During the nine months ended September 30, 2022, $280 thousand of the December 31, 2021, deferred revenues balance was recognized as revenues.
Schedule of concentration of credit risk	September 30, December 31, 2022 2021 Customer A 27 % 12 % Customer B 27 % * ) Customer C 19 % * ) Customer D 18 % * ) Customer E * ) 20 % Customer F * ) 18 % Customer G * ) 16 % Customer H * ) 10 % *) Less than 10%
Schedule of product warranty liability	US Dollars in thousands Balance at December 31, 2021 $ 112 Provision 245 Usage (265 ) Balance at September 30, 2022 $ 92

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of inventories	September 30, December 31, 2022 2021 Finished products $ 2,807 $ 2,284 Raw materials 523 705 $ 3,330 $ 2,989

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease commitments	2022 $ 165 2023 520 2024 57 2025 14 Total lease payments 756 Less: imputed interest (65 ) Present value of future lease payments 691 Less: current maturities of operating leases (606 ) Non-current operating leases $ 85 Weighted-average remaining lease term (in years) 1.51 Weighted-average discount rate 12.5 %

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2022
Share-based Payment Arrangement [Abstract]
Schedule of employee options activity	Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) O 61,832 $ 38.34 4.55 $ - Granted - - - - Exercised - - - - Forfeited (17,838 ) 31.13 - - O 43,994 $ 41.27 4.64 $ - O 42,440 $ 42.58 4.57 $ -
Schedule of employee RSUs activity	Number of shares underlying outstanding RSUs Weighted average grant date fair value U 1,356,284 $ 1.61 Granted 2,152,757 1.00 Vested (421,782 ) 1.65 Forfeited (210,641 ) 1.53 U 2,876,618 $ 1.15
Schedule of options and RSUs outstanding	Range of exercise price Options outstanding September 30, Weighted average remaining contractual life (years) (1) Options and September 30, Weighted average remaining contractual life (years) (1) RSUs only 2,876,618 - - - $5.37 12,425 6.49 10,871 6.49 $20.42 - $33.75 13,317 5.46 13,317 5.46 $37.14 - $38.75 8,946 1.23 8,946 1.23 $50 - $52.5 6,731 4.72 6,731 4.72 $182.5 - $524.25 2,575 3.10 2,575 3.10 2,920,612 4.64 42,440 4.57 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of warrants outstanding and exercisable	Issuance date Warrants outstanding Exercise price per warrant Warrants outstanding exercisable Contractual term (number) (number) December 31, 2015 (1) 4,771 $ 7.500 4,771 See footnote (1) December 28, 2016 (2) 1,908 $ 7.500 1,908 See footnote (1) November 20, 2018 (3) 126,839 $ 7.500 126,839 November 20, 2023 November 20, 2018 (4) 106,680 $ 9.375 106,680 November 15, 2023 February 25, 2019 (5) 45,600 $ 7.187 45,600 February 21, 2024 April 5, 2019 (6) 408,457 $ 5.140 408,457 October 7, 2024 April 5, 2019 (7) 49,015 $ 6.503 49,015 April 3, 2024 June 5, 2019, and June 6, 2019 (8) 1,464,665 $ 7.500 1,464,665 June 5, 2024 June 5, 2019 (9) 87,880 $ 9.375 87,880 June 5, 2024 June 12, 2019 (10) 416,667 $ 6.000 416,667 December 12, 2024 June 10, 2019 (11) 50,000 $ 7.500 50,000 June 10, 2024 February 10, 2020 (12) 28,400 $ 1.250 28,400 February 10, 2025 February 10, 2020 (13) 105,840 $ 1.563 105,840 February 10, 2025 July 6, 2020 (14) 448,698 $ 1.760 448,698 January 2, 2026 July 6, 2020 (15) 296,297 $ 2.278 296,297 January 2, 2026 December 8, 2020 (16) 586,760 $ 1.340 586,760 June 8, 2026 December 8, 2020 (17) 108,806 $ 1.792 108,806 June 8, 2026 February 26, 2021 (18) 5,460,751 $ 3.600 5,460,751 August 26, 2026 February 26, 2021 (19) 655,290 $ 4.578 655,290 August 26, 2026 September 29, 2021 (20) 8,006,759 $ 2.000 8,006,759 March 29, 2027 September 29, 2021 (21) 960,811 $ 2.544 960,811 September 27, 2026 19,420,894 19,420,894 (1) Represents warrants for ordinary shares issuable upon an exercise price of $7.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2022. (2) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (3) Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018. (4) Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018. (5) Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019. (6) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019. (7) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering. (8) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively. (9) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants. (10) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. (11) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants (12) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. During the year ended December 31, 2021, 3,740,100 warrants were exercised for total consideration of $4,675,125. (13) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. During the year ended December 31, 2021, 230,160 warrants were exercised for total consideration of $359,625. (14) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. During the year ended December 31, 2021, 2,020,441 warrants were exercised for total consideration of $3,555,976. (15) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. (16) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. During the year ended December 31, 2021, 3,598,072 warrants were exercised for total consideration of $4,821,416. (17) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. During the year ended December 31, 2021, 225,981 warrants were exercised for total consideration of $405,003. (18) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021. (19) Represents warrants that were issued to the placement agent as compensation for its role in Company’s private placement offering in February 2021. (20) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021. (21) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.
Schedule of non-cash share-based compensation expense	Nine Months Ended September 30, 2022 2021 Cost of revenues $ 10 $ 7 Research and development 60 34 Sales and marketing 167 120 General and administrative 409 438 Total $ 646 $ 599

FINANCIAL EXPENSES (INCOME), _2

FINANCIAL EXPENSES (INCOME), NET (Tables)	9 Months Ended
	Sep. 30, 2022
Other Income and Expenses [Abstract]
Schedule of financial expenses, net	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Foreign currency transactions and other $ 1 $ 22 $ 50 $ (6 ) Bank commissions - 5 19 20 $ 1 $ 27 $ 69 $ 14

GEOGRAPHIC INFORMATION AND MA_2

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of revenues within geographic areas	September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenues based on customer’s location: United States $ 395 $ 821 $ 1,193 $ 1,951 Europe 488 1,148 2,023 2,711 Asia-Pacific 2 1 113 58 Africa 1 2 3 4 Total revenues $ 886 $ 1,972 $ 3,332 $ 4,724
Schedule of long-lived assets by geographic region	September 30, December 31, 2022 2021 Long-lived assets by geographic region (*): Israel $ 515 $ 629 United States 303 493 Germany 57 43 $ 875 $ 1,165 *) Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.
Schedule of major customer data as a percentage of total revenues	Nine Months Ended eptember 30, 2022 2021 Major customer data as a percentage of total revenues: Customer A 21.8 % * ) Customer B * ) 12.1 % *) Less than 10%.

GENERAL (Details)

GENERAL (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
General (Textual)
Net loss	$ (5,460)	$ (2,675)	$ (14,256)	$ (8,878)
Accumulated deficit	208,437		208,437		$ 194,181
Cash and cash equivalents	$ 74,027		74,027		$ 88,337
Negative cash flow from operations			$ (13,978)	$ (8,903)

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total Revenues	$ 886	$ 1,972	$ 3,332	$ 4,724
Units placed [Member]
Total Revenues	751	1,855	2,986	4,310
Spare parts and warranties [Member]
Total Revenues	$ 135	$ 117	$ 346	$ 414

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Trade receivable, net	[1]	$ 447	$ 585
Deferred revenues	[1],[2]	$ 1,177	$ 1,182
[1]Balance presented net of unrecognized revenues that were not yet collected.[2]During the nine months ended September 30, 2022, $280 thousand of the December 31, 2021, deferred revenues balance was recognized as revenues.

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - Trade Receivables [Member] - Credit Concentration Risk [Member]	9 Months Ended		12 Months Ended
	Sep. 30, 2022		Dec. 31, 2021
Customer A [Member]
Concentration Risk [Line Items]
Concentration of credit risk	27%		12%	[1]
Customer B [Member]
Concentration Risk [Line Items]
Concentration of credit risk	27%			[1]
Customer C [Member]
Concentration Risk [Line Items]
Concentration of credit risk	19%			[1]
Customer D [Member]
Concentration Risk [Line Items]
Concentration of credit risk	18%	[1]
Customer E [Member]
Concentration Risk [Line Items]
Concentration of credit risk		[1]	20%
Customer F [Member]
Concentration Risk [Line Items]
Concentration of credit risk		[1]	18%
Customer G [Member]
Concentration Risk [Line Items]
Concentration of credit risk		[1]	16%
Customer H [Member]
Concentration Risk [Line Items]
Concentration of credit risk		[1]	10%
[1]Less than 10%

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details 3) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Warranty provision:
Balance at December 31, 2021	$ 112
Provision	245
Usage	(265)
Balance at June 30, 2022	$ 92

SIGNIFICANT ACCOUNTING POLICI_8

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Significant Accounting Policies (Textual)
Allowance for credit losses	$ 26	$ 26	$ 42
Sales return reserve		52	$ 43
Deferred revenues recognized		$ 280
Performance obligation, description		The Company’s unfilled performance obligations as of September 30, 2022, and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1.1 million, which is fulfilled over one to five years.
Number of ordinary shares excluded from the calculations of diluted loss per share	19,420,894	19,420,894
SCI Products [Member]
Significant Accounting Policies (Textual)
Service policy	2 years	2 years
ReStore product [Member]
Significant Accounting Policies (Textual)
Service policy	2 years	2 years
Distributed Products [Member] | Minimum [Member]
Significant Accounting Policies (Textual)
Service policy	1 year	1 year
Distributed Products [Member] | Maximum [Member]
Significant Accounting Policies (Textual)
Service policy	10 years	10 years

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished products	$ 2,807	$ 2,284
Raw materials	523	705
Inventories	$ 3,330	$ 2,989

INVENTORIES (Details Textual)

INVENTORIES (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Inventory Disclosure [Abstract]
Write off inventory	$ 32	$ 65

COMMITMENTS AND CONTINGENT LI_3

COMMITMENTS AND CONTINGENT LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
2022	$ 165
2023	520
2024	57
2025	14
Total lease payments	756
Less: imputed interest	(65)
Present value of future lease payments	691
Less: current maturities of operating leases	(606)	$ (641)
Non-current operating leases	$ 85	$ 418
Weighted-average remaining lease term (in years)	1 year 6 months 3 days
Weighted-average discount rate	12.50%

COMMITMENTS AND CONTINGENT LI_4

COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Commitments and Contingent Liabilities (Textual)
Non-cancelable outstanding obligations	$ 1,600		$ 1,600
Total fund received			208
Royalties expenses	3	$ 2	$ 7	$ 8
Lease expiration, term			These leases in Israel and United States will expire in 2023 while the operating lease in Germany is renewed every month.
Other long-term assets	655		$ 655
Lease expense	175	$ 179	$ 538	543
IPO [Member]
Commitments and Contingent Liabilities (Textual)
Description of conversion ratio			ordinary shares in a conversion ratio of 1 to 1
RRL and RRG [Member]
Commitments and Contingent Liabilities (Textual)
Maximum penalties payable on early release of agreement	18		$ 18
Lease expiration, term			RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2022 and 2025.
IIA [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received			$ 2,350
Total fund received as research and development efforts	23		207
Royalty bearing grants				$ 1,570
Royalties paid			$ 110
Percentage of obligation to pay royalties			3%
Contingent liability	$ 1,600		$ 1,600
Percentage of grant received			100%
IIA [Member] | Convertible preferred A shares [Member]
Commitments and Contingent Liabilities (Textual)
Amount received in consideration of preferred shares			$ 400
Convertible preferred shares	209		209
BIRD [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received			$ 500

RESEARCH COLLABORATION AGREEM_2

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Research Collaboration Agreement and License Agreement (Textual)
Research and development, net		$ 1,065	$ 638	$ 2,928	$ 2,243
Harvard License Agreement and Collaboration Agreement [Member]
Research Collaboration Agreement and License Agreement (Textual)
Research and development, net		$ 26	$ 14	$ 60	$ 334
Research collaboration agreement expire date	May 16, 2022

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Number, Options outstanding at the beginning of the period	61,832
Number, Granted	0
Number, Exercised	0
Number, Forfeited	(17,838)
Number, Options outstanding at the end of the period	43,994	61,832
Number, Options exercisable at the end of the period	42,440
Average exercise price, Options outstanding at the beginning of the period	$ 38.34
Average exercise price, Granted	0
Average exercise price, Exercised	0
Average exercise price, Forfeited	31.13
Average exercise price, Options outstanding at the end of the period	41.27	$ 38.34
Average exercise price, Options exercisable at the end of the period	$ 42.58
Average remaining contractual life (in years), Options outstanding at the beginning of the period	4 years 7 months 20 days	4 years 6 months 18 days
Average remaining contractual life (in years), Options exercisable at the end of the period	4 years 6 months 25 days
Aggregate intrinsic value (in thousands), Options outstanding	$ 0	$ 0
Aggregate intrinsic value (in thousands), Options exercisable at the end of the period	$ 0

SHAREHOLDERS' EQUITY (Details 1

SHAREHOLDERS' EQUITY (Details 1) - Employee and Non-Employee RSUs [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of shares underlying outstanding RSUs
Unvested RSUs at the Beginning of the period | shares	1,356,284
Granted | shares	2,152,757
Vested | shares	(421,782)
Forfeited | shares	(210,641)
Unvested RSUs at the end of the period | shares	2,876,618
Weighted average grant date fair value
Unvested RSUs at the Beginning of the period | $ / shares	$ 1.61
Granted | $ / shares	1
Vested | $ / shares	1.65
Forfeited | $ / shares	1.53
Unvested RSUs at the end of the period | $ / shares	$ 1.15

SHAREHOLDERS' EQUITY (Details 2

SHAREHOLDERS' EQUITY (Details 2) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	2,920,612
Options outstanding weighted average remaining contractual life (years)	4 years 7 months 20 days	[1]
Options outstanding and exercisable	42,440
Options exercisable weighted average remaining contractual life (years)	4 years 6 months 25 days	[1]
RSUs only [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
RSUs outstanding	2,876,618
5.37 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 5.37
Options outstanding	12,425
Options outstanding weighted average remaining contractual life (years)	6 years 5 months 26 days	[1]
Options outstanding and exercisable	10,871
Options exercisable weighted average remaining contractual life (years)	6 years 5 months 26 days	[1]
20.42 - 33.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 20.42
Range of exercise price, maximum | $ / shares	$ 33.75
Options outstanding	13,317
Options outstanding weighted average remaining contractual life (years)	5 years 5 months 15 days	[1]
Options outstanding and exercisable	13,317
Options exercisable weighted average remaining contractual life (years)	5 years 5 months 15 days	[1]
37.14 - 38.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 37.14
Range of exercise price, maximum | $ / shares	$ 38.75
Options outstanding	8,946
Options outstanding weighted average remaining contractual life (years)	1 year 2 months 23 days	[1]
Options outstanding and exercisable	8,946
Options exercisable weighted average remaining contractual life (years)	1 year 2 months 23 days	[1]
50 - 52.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 50
Range of exercise price, maximum | $ / shares	$ 52.5
Options outstanding	6,731
Options outstanding weighted average remaining contractual life (years)	4 years 8 months 19 days	[1]
Options outstanding and exercisable	6,731
Options exercisable weighted average remaining contractual life (years)	4 years 8 months 19 days	[1]
182.5 - 524.25 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 182.5
Range of exercise price, maximum | $ / shares	$ 524.25
Options outstanding	2,575
Options outstanding weighted average remaining contractual life (years)	3 years 1 month 6 days	[1]
Options outstanding and exercisable	2,575
Options exercisable weighted average remaining contractual life (years)	3 years 1 month 6 days	[1]
[1]Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

SHAREHOLDERS' EQUITY (Details 3

SHAREHOLDERS' EQUITY (Details 3)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Class of Warrant or Right [Line Items]
Warrants outstanding	19,420,894
Warrants outstanding and exercisable	19,420,894
December 31, 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	4,771	[1]
Exercise price per warrant | $ / shares	$ 7.5	[1]
Warrants outstanding and exercisable	4,771	[1]
December 28, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,908	[2]
Exercise price per warrant | $ / shares	$ 7.5	[2]
Warrants outstanding and exercisable	1,908	[2]
November 20, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	126,839	[3]
Exercise price per warrant | $ / shares	$ 7.5	[3]
Warrants outstanding and exercisable	126,839	[3]
Contractual term	Nov. 20, 2023	[3]
November 20, 2018 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	106,680	[4]
Exercise price per warrant | $ / shares	$ 9.375	[4]
Warrants outstanding and exercisable	106,680	[4]
Contractual term	Nov. 15, 2023	[4]
February 25, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	45,600	[5]
Exercise price per warrant | $ / shares	$ 7.187	[5]
Warrants outstanding and exercisable	45,600	[5]
Contractual term	Feb. 21, 2024	[5]
April 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	408,457	[6]
Exercise price per warrant | $ / shares	$ 5.14	[6]
Warrants outstanding and exercisable	408,457	[6]
Contractual term	Oct. 07, 2024	[6]
April 5, 2019 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	49,015	[7]
Exercise price per warrant | $ / shares	$ 6.503	[7]
Warrants outstanding and exercisable	49,015	[7]
Contractual term	Apr. 03, 2024	[7]
June 5, 2019 and June 6, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,464,665	[8]
Exercise price per warrant | $ / shares	$ 7.5	[8]
Warrants outstanding and exercisable	1,464,665	[8]
Contractual term	Jun. 05, 2024	[8]
June 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	87,880	[9]
Exercise price per warrant | $ / shares	$ 9.375	[9]
Warrants outstanding and exercisable	87,880	[9]
Contractual term	Jun. 05, 2024	[9]
June 12, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	416,667	[10]
Exercise price per warrant | $ / shares	$ 6	[10]
Warrants outstanding and exercisable	416,667	[10]
Contractual term	Dec. 12, 2024	[10]
June 10, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	50,000	[11]
Exercise price per warrant | $ / shares	$ 7.5	[11]
Warrants outstanding and exercisable	50,000	[11]
Contractual term	Jun. 10, 2024	[11]
February 10, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	28,400	[12]
Exercise price per warrant | $ / shares	$ 1.25	[12]
Warrants outstanding and exercisable	28,400	[12]
Contractual term	Feb. 10, 2025	[12]
February 10, 2020 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	105,840	[13]
Exercise price per warrant | $ / shares	$ 1.563	[13]
Warrants outstanding and exercisable	105,840	[13]
Contractual term	Feb. 10, 2025	[13]
July 6, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	448,698	[14]
Exercise price per warrant | $ / shares	$ 1.76	[14]
Warrants outstanding and exercisable	448,698	[14]
Contractual term	Jan. 02, 2026	[14]
July 6, 2020 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	296,297	[15]
Exercise price per warrant | $ / shares	$ 2.278	[15]
Warrants outstanding and exercisable	296,297	[15]
Contractual term	Jan. 02, 2026	[15]
December 8, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	586,760	[16]
Exercise price per warrant | $ / shares	$ 1.34	[16]
Warrants outstanding and exercisable	586,760	[16]
Contractual term	Jun. 08, 2026	[16]
December 8, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	108,806	[17]
Exercise price per warrant | $ / shares	$ 1.792	[17]
Warrants outstanding and exercisable	108,806	[17]
Contractual term	Jun. 08, 2026	[17]
February 26, 2021 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	5,460,751	[18]
Exercise price per warrant | $ / shares	$ 3.6	[18]
Warrants outstanding and exercisable	5,460,751	[18]
Contractual term	Aug. 26, 2026	[18]
February 26, 2021 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	655,290	[19]
Exercise price per warrant | $ / shares	$ 4.578	[19]
Warrants outstanding and exercisable	655,290	[19]
Contractual term	Aug. 26, 2026	[19]
September 29, 2021 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	8,006,759	[20]
Exercise price per warrant | $ / shares	$ 2	[20]
Warrants outstanding and exercisable	8,006,759	[20]
Contractual term	Mar. 29, 2027	[20]
September 29, 2021 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	960,811	[21]
Exercise price per warrant | $ / shares	$ 2.544	[21]
Warrants outstanding and exercisable	960,811	[21]
Contractual term	Sep. 27, 2026	[21]
[1]Represents warrants for ordinary shares issuable upon an exercise price of $7.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2022.[2]Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.[3]Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018.[4]Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018.[5]Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019.[6]Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.[7]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.[8]Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.[9]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.[10]Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.[11]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.[12]Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. During the year ended December 31, 2021, 3,740,100 warrants were exercised for total consideration of $4,675,125.[13]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. During the year ended December 31, 2021, 230,160 warrants were exercised for total consideration of $359,625.[14]Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. During the year ended December 31, 2021, 2,020,441 warrants were exercised for total consideration of $3,555,976.[15]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.[16]Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. During the year ended December 31, 2021, 3,598,072 warrants were exercised for total consideration of $4,821,416.[17]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. During the year ended December 31, 2021, 225,981 warrants were exercised for total consideration of $405,003.[18]Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021.[19]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s private placement offering in February 2021 (the “February 2021 Offering”).[20]Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.[21]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.

SHAREHOLDERS' EQUITY (Details 4

SHAREHOLDERS' EQUITY (Details 4) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 646	$ 599
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	10	7
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	60	34
Sales and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	167	120
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 409	$ 438

SHAREHOLDERS' EQUITY (Details T

SHAREHOLDERS' EQUITY (Details Textual) $ / shares in Units, $ in Thousands

1 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Feb. 19, 2021 ₪ / shares shares

Jun. 30, 2022 shares

Sep. 30, 2022 USD ($) $ / shares

Sep. 30, 2021 $ / shares

Dec. 31, 2021 USD ($)

Dec. 31, 2015 $ / shares

Sep. 30, 2022 ₪ / shares

Sep. 30, 2022 USD ($) $ / shares shares

Jun. 02, 2022 ₪ / shares

Jun. 02, 2022 USD ($)

Dec. 31, 2021 ₪ / shares shares

Feb. 19, 2021 $ / shares shares

Dec. 28, 2016 USD ($)

Shareholders' Equity (Textual)

Description of wainwright or its designees warrants to purchase

the Company signed a purchase agreement with certain institutional investors for the issuance and sale of 15,403,014 ordinary shares, par value NIS 0.25 per share, pre-funded warrants to purchase up to an aggregate of 610,504 ordinary shares and ordinary warrants to purchase up to an aggregate of 8,006,759 ordinary shares at an exercise price of $2.00 per share. The Pre-Funded Warrants have an exercise price of $0.001 per Ordinary Share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary share was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). The offering of the ordinary shares, the pre-funded warrants and the ordinary shares that are issuable from time to time upon exercise of the pre-funded warrants was made pursuant to the Company’s shelf registration statement on Form S-3 initially filed with the Securities and Exchange Commission (“SEC”) on May 9, 2019, and declared effective by the SEC on May 23, 2019, and the ordinary warrants were issued in a concurrent private placement. The ordinary warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending five and one-half years from the date of issuance. All of the pre-funded warrants were exercised in full on September 27, 2021, and the offering closed on September 29, 2021. Additionally, the Company issued warrants to purchase up to 960,811 ordinary shares, with an exercise price of $2.5438 per share, exercisable from September 27, 2021, until September 27, 2026, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our September 2021 registered direct offering.

Authorized value of stock repurchased | $

$ 8,000

Per share value of stock repurchase authorized | ₪ / shares

₪ 0.25

₪ 0.25

₪ 0.25

Treasury Stock, Shares

184,629

Total cost | $

$ 183,540

Securities Purchase Agreements [Member]

Shareholders' Equity (Textual)

Number of warrants issued

9,814,754

Warrants exercisable, description

exercisable from February 19, 2021 until August 26, 2026.

Total gross exercised | $

$ 13,800

Securities Purchase Agreements [Member] | Minimum [Member]

Shareholders' Equity (Textual)

Exercise price per share | $ / shares

$ 1.25

Securities Purchase Agreements [Member] | Maximum [Member]

Shareholders' Equity (Textual)

Exercise price per share | $ / shares

$ 1.79

Certain institutional purchasers [Member] | Offering of ordinary shares in February 2020 [Member]

Shareholders' Equity (Textual)

Number of warrants issued

3,740,100

Proceeds from warrants | $

$ 4,675,125

Certain institutional purchasers [Member] | Registered direct offering of ordinary shares in July 2020 [Member]

Shareholders' Equity (Textual)

Number of warrants issued

2,020,441

Proceeds from warrants | $

3,555,976

Certain institutional purchasers [Member] | Offering of ordinary shares in December 2020 [Member]

Shareholders' Equity (Textual)

Number of warrants issued

3,598,072

Proceeds from warrants | $

4,821,416

Placement agent [Member] | February 2020 best efforts offering [Member]

Shareholders' Equity (Textual)

Number of warrants issued

230,160

Proceeds from warrants | $

359,625

Placement agent [Member] | December 2020 private placement [Member]

Shareholders' Equity (Textual)

Number of warrants issued

225,981

Proceeds from warrants | $

$ 405,003

Purchase agreement with certain institutional investors [Member]

Shareholders' Equity (Textual)

Exercise price per share | $ / shares

$ 3.6

Number of warrants issued

5,460,751

5,460,751

Issuance of ordinary shares, shares

10,921,502

Exercise price ordinary shares | $ / shares

$ 3.6625

Purchase agreement with certain institutional investors [Member] | Additionally Warrants Issued [Member]

Shareholders' Equity (Textual)

Exercise price per share | $ / shares

$ 4.578125

Number of warrants issued

655,290

655,290

Purchase agreement with certain institutional investors [Member] | NIS [Member]

Shareholders' Equity (Textual)

Exercise price ordinary shares | ₪ / shares

₪ 0.25

Kreos Capital V [Member]

Shareholders' Equity (Textual)

Warrants grant date

Dec. 31, 2015

Warrants exercisable, description

currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2022.

Kreos Capital [Member]

Shareholders' Equity (Textual)

Exercise price per share | $ / shares

$ 7.5

Drawdown amount under loan agreement | $

$ 8,000

Employee Stock Option [Member]

Shareholders' Equity (Textual)

Award vesting period, description

Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year.

Shares reserved for future issuance (in shares)

2,934,679

233,957

Unrecognized cost of shares | $

$ 3,000

Expected term of shares

2 years 10 months 24 days

Restricted Stock Units (RSUs) [Member]

Shareholders' Equity (Textual)

Weighted average grant date fair value, options (in USD per share) | $ / shares

$ 1

$ 1.69

Restricted Stock Units (RSUs) [Member] | Nonemployee [Member]

Shareholders' Equity (Textual)

Granted

47,522

FINANCIAL EXPENSES (INCOME), _3

FINANCIAL EXPENSES (INCOME), NET (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ 1	$ 22	$ 50	$ (6)
Bank commissions	0	5	19	20
Financial expenses, net	$ 1	$ 27	$ 69	$ 14

GEOGRAPHIC INFORMATION AND MA_3

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue, Major Customer [Line Items]
Total revenues	$ 886	$ 1,972	$ 3,332	$ 4,724
United States [Member]
Revenue, Major Customer [Line Items]
Total revenues	395	821	1,193	1,951
Europe [Member]
Revenue, Major Customer [Line Items]
Total revenues	488	1,148	2,023	2,711
Asia-Pacific [Member]
Revenue, Major Customer [Line Items]
Total revenues	2	1	113	58
Africa [Member]
Revenue, Major Customer [Line Items]
Total revenues	$ 1	$ 2	$ 3	$ 4

GEOGRAPHIC INFORMATION AND MA_4

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets		$ 875	$ 1,165
Israel [Mmeber]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	515	629
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	303	493
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	$ 57	$ 43
[1]Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.

GEOGRAPHIC INFORMATION AND MA_5

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2) - Sales Revenue, Net [Member] - Customer Concentration Risk [Member]	9 Months Ended
	Sep. 30, 2022		Sep. 30, 2021
Revenue, Major Customer [Line Items]
Concentration risk threshold percentage	10%
Customer A [Member]
Revenue, Major Customer [Line Items]
Concentration risk	21.80%			[1]
Customer B [Member]
Revenue, Major Customer [Line Items]
Concentration risk		[1]	12.10%
[1]Less than 10%.

GEOGRAPHIC INFORMATION AND MA_6

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual)	9 Months Ended
	Sep. 30, 2022 segment
Geographic Information and Major Customer and Product Data (Textual)
Number of reportable segments	1

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($) $ in Thousands	Oct. 01, 2022	Jun. 02, 2022
Subsequent Event [Line Items]
Authorized value of stock repurchased		$ 8,000
Subsequent Event
Subsequent Event [Line Items]
Authorized number of stock repurchased	719,893
Authorized value of stock repurchased	$ 679,844